By Alex Philippidis | June 12, 2024
Credit: koto_feja/Getty Images
Alzheon says it expects to fund the completion of a pivotal Phase III trial and regulatory filings later this year for its lead candidate, a treatment for early Alzheimer’s disease (AD), with proceeds from a $100 million Series E financing the company said it completed today.
ALZ-801, also called valiltramiprosate, is under study in the Phase III APOLLOE4 trial (NCT04770220), which is fully enrolled with 325 patients who were screened from more than 6,000 patients. APOLLOE4 is designed to assess the safety and efficacy of ALZ-801 compared to placebo in early Alzheimer’s patients—specifically carriers of two ε4 alleles of apolipoprotein E gene (APOE4/4 homozygotes), who have the highest genetic risk of Alzheimer’s disease.
Read the full article here
Source: GEN
